Gujarat Themis Biosyn Limited — PPTs, 01-08-2025: Investor Presentation

Here's a summary of the attached document:

**1. Financial Highlights:**

GTBL posted Q1 FY26 revenue of Rs. 35.9 Cr, EBITDA Rs. 13.9 Cr (38.8% margin), PAT Rs. 9.1 Cr (25.2% margin). Margins impacted by inventory volatility, power issues, and one-off expenses. High capital work in progress (Rs. 184.41 Cr) reflects heavy ongoing investment.

**2. Strategic Initiatives & Growth Drivers:**

Growth from forward integration: new API unit operational since May 2025, targeting US/Europe exports. Fermentation capacity expanding, due end-year. New R&D unit developing molecules; Q1 R&D spend ~6% of revenue.

**3. Business Developments:**

New API unit began commercial operations. A 1:2 bonus share issue completed. Continues to produce specialized fermentation-based intermediates Rifamycin S/O.

**4. Market Position & Competitive Advantage:**

A leader in fermentation-based intermediates, GTBL pioneered commercial Rifampicin production. Niche products and fungible capacities (16,000 KG/month) solidify its edge.

**5. Investor Implications:**

Despite Q1 headwinds, major investments in API production and capacity expansion signal strong growth potential. R&D and export focus suggest long-term value; successful ramp-up of new facilities is crucial.